ResearcherSeoul National UniversityActive in the last 2 years
Hye Jin Choi
Matched on ORCID iD 0000-0001-5917-1400; OpenAlex author ID A5071819927, A5159736734. Sources: OpenAlex.
Their work
- Papers
- 19 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 81
2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 3 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 4 papers · 2025: 1 paper · 2026: 1 paper
Papers 19
- Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized contro… Co-author DOI 10.1186/s12885-026-15639-6↗
- Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable pancreatic cancer treated with modified… Last author DOI 10.1016/j.eclinm.2025.103646↗
- Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicen… Co-author DOI 10.1016/j.ejca.2024.114194↗
- Inhibition of the Alternative Complement Pathway May Cause Secretion of Factor B, Enabling an Early Detection of Pancreatic Cancer. Co-author DOI 10.1021/acs.jproteome.3c00695↗
- Deep-Transfer-Learning-Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Ca… Co-author DOI 10.1200/cci.24.00021↗
- Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Co-author DOI 10.2217/fon-2023-0963↗
- Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adapti… Co-author DOI 10.1016/j.eclinm.2023.101897↗
- Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicent… Last author DOI 10.1016/j.esmoop.2021.100049↗
- Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Promoting Role. Co-author DOI 10.1021/acs.jproteome.1c00805↗
- Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. Co-author DOI 10.1111/cas.14264↗
- Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korea… Co-author DOI 10.1177/1758835919871126↗
- Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells. Co-author DOI 10.1007/s10495-015-1208-z↗
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
- Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnics: A Large Population-Based Observational Study. Co-author DOI 10.1097/md.0000000000003472↗
- Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells. First author DOI 10.1016/j.cellsig.2015.01.007↗
- Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer. Co-author DOI 10.2967/jnumed.113.131847↗
- Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy. Co-author DOI 10.3349/ymj.2014.55.6.1498↗
- Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer. Co-author DOI 10.3349/ymj.2013.54.6.1377↗
- Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. Co-author DOI 10.1007/s11605-011-1784-3↗
Closest collaborators
The 25 strongest of 81 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Choong‐kun Lee · 6 shared papers, 2021–2025 · strength 1.04
- Paper Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable… DOI 10.1016/j.eclinm.2025.103646↗
- Paper Inhibition of the Alternative Complement Pathway May Cause Secretion of Factor B, Enabling an Early Detection of Pancre… DOI 10.1021/acs.jproteome.3c00695↗
- Paper Deep-Transfer-Learning-Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting… DOI 10.1200/cci.24.00021↗
- Changhoon Yoo · 4 shared papers, 2019–2024 · strength 0.56
- Paper Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal aden… DOI 10.2217/fon-2023-0963↗
- Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
- Sung Hyun Kim · 3 shared papers, 2021–2024 · strength 0.51
- Paper Inhibition of the Alternative Complement Pathway May Cause Secretion of Factor B, Enabling an Early Detection of Pancre… DOI 10.1021/acs.jproteome.3c00695↗
- Paper Deep-Transfer-Learning-Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting… DOI 10.1200/cci.24.00021↗
- Paper Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Prom… DOI 10.1021/acs.jproteome.1c00805↗
- Do‐Youn Oh · 4 shared papers, 2019–2026 · strength 0.51
- Paper Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, mul… DOI 10.1186/s12885-026-15639-6↗
- Paper Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metasta… DOI 10.1016/j.eclinm.2023.101897↗
- Paper Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. DOI 10.1111/cas.14264↗
- Chang Moo Kang · 5 shared papers, 2012–2024 · strength 0.43
- Paper Inhibition of the Alternative Complement Pathway May Cause Secretion of Factor B, Enabling an Early Detection of Pancre… DOI 10.1021/acs.jproteome.3c00695↗
- Paper Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Prom… DOI 10.1021/acs.jproteome.1c00805↗
- Paper Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with … DOI 10.2967/jnumed.113.131847↗
- Makoto Ueno · 2 shared papers, 2023–2024 · strength 0.34
- Paper Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal aden… DOI 10.2217/fon-2023-0963↗
- Paper Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metasta… DOI 10.1016/j.eclinm.2023.101897↗
- Min Jung Lee · 2 shared papers, 2021–2024 · strength 0.32
- Paper Inhibition of the Alternative Complement Pathway May Cause Secretion of Factor B, Enabling an Early Detection of Pancre… DOI 10.1021/acs.jproteome.3c00695↗
- Paper Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Prom… DOI 10.1021/acs.jproteome.1c00805↗
- Young‐Ki Paik · 2 shared papers, 2021–2024 · strength 0.32
- Paper Inhibition of the Alternative Complement Pathway May Cause Secretion of Factor B, Enabling an Early Detection of Pancre… DOI 10.1021/acs.jproteome.3c00695↗
- Paper Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Prom… DOI 10.1021/acs.jproteome.1c00805↗
- Joon Oh Park · 3 shared papers, 2019–2021 · strength 0.28
- Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
- Paper Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. DOI 10.1111/cas.14264↗
- Paper Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancrea… DOI 10.1177/1758835919871126↗
- Kyu‐pyo Kim · 2 shared papers, 2019–2024 · strength 0.26
- Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
- Paper Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancrea… DOI 10.1177/1758835919871126↗
- Baek‐Yeol Ryoo · 2 shared papers, 2019–2024 · strength 0.26
- Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
- Paper Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancrea… DOI 10.1177/1758835919871126↗
- Jung Ho Kim · 1 shared paper, 2025 · strength 0.25
- Chung‐Pin Li · 2 shared papers, 2020–2023 · strength 0.24
- Paper Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metasta… DOI 10.1016/j.eclinm.2023.101897↗
- Paper Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. DOI 10.1111/cas.14264↗
- Ho Kyoung Hwang · 2 shared papers, 2012–2024 · strength 0.23
- Paper Deep-Transfer-Learning-Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting… DOI 10.1200/cci.24.00021↗
- Paper Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in bo… DOI 10.1007/s11605-011-1784-3↗
- Ángela Lamarca Lete · 1 shared paper, 2024 · strength 0.20
- Arndt Vogel · 1 shared paper, 2024 · strength 0.20
- Michael Jon Pishvaian · 1 shared paper, 2024 · strength 0.20
- Chigusa Morizane · 1 shared paper, 2024 · strength 0.20
- Mi‐Suk Park · 1 shared paper, 2024 · strength 0.20
- Seung‐seob Kim · 1 shared paper, 2024 · strength 0.20
- Sunkyu Kim · 1 shared paper, 2024 · strength 0.20
- Michael Cecchini · 1 shared paper, 2024 · strength 0.20
- Julian Choi · 1 shared paper, 2026 · strength 0.19
- Jin-Young Jang · 1 shared paper, 2026 · strength 0.19
- Ju Won Kim · 1 shared paper, 2026 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.